INTRODUCTION
There is a largely unmet clinical need for the repair and regeneration of human tissues and organs. Due to the limitations of conventional clinical therapies, tissue engineering, a multidisciplinary area of research, has gained prominence, as it is likely to offer novel solutions to healthcare problems. Some early success has been achieved in transplanting relatively simple tissues or organs such as the trachea 1 and the bladder. 2 These early accomplishments demonstrate the massive potential of utilising tissue engineering approaches to restore tissue and organ function, although much further research is needed, especially for more complicated organs and tissues.
Stem cells are an exciting cell source, with the potential to be differentiated into the specific lineages required for the repair and restoration of functional tissues. Increased reporting of the limitations of current methods of using stem cells in tissue engineering has galvanised research to investigate new methods of controlling stem cell fate. However, effectively controlling stem cell proliferation and differentiation, with minimum side effects, is very challenging.
It has become apparent in recent years that 'epigenetics' plays a massive role in cell fate. 'Epigenetics' refers to the post-genetic modifications made to DNA sequences and related proteins, where chemical functional groups such as methyl or acetyl are transferred onto the DNA or such related protein (e.g., the histone scaffolds, which DNA is wrapped around). Epigenetic modifications make no changes to the actual base genomic code, and epigenetic changes are potentially heritable. 3, 4 Many diseases, perhaps most notably cancers, have epigenetics as a key mediator. [5] [6] [7] More specifically, research has discovered that modifications to the histone, such as those by histone deacetylation enzymes (HDACs), affect chromatin structure, and thus stem cell properties such as potency and differentiation. 3, 8, 9 As such, the epigenetic make-up of a cell may be crucial for cell-based therapies and tissue engineering. For example, inhibition of HDACs has been utilised to improve in vitro expansion methods of human hematopoietic stem cells, 10 to improve bone differentiation of mesenchymal stem cells (MSCs), 11 to enhance the efficiency of induced pluripotent stem cell (iPSC) generation, 8 and to increase the efficiency of cellular therapies. 12 This review will explore background knowledge of epigenetics, the structure, and function of HDACs and their inhibitors, highlight the current uses of and potential of these compounds in cellbased therapies and tissue engineering and suggest where this field may find itself in the future.
EPIGENETICS: POST-GENETIC MODIFICATIONS OF DNA SEQUENCE DNA, the set of 'rules' which control the cell in its most basic form, exists as the famous double helix, is packed into tight but flexible assemblies. 13 This flexibility allows constant structural alteration so that DNA can be utilised in transcription, replication, and repair. 14 The 147 base units of DNA wrap around histone proteins, forming nucleosomes. These can be organised further, with the everchanging histone epigenome affecting how compact or how relaxed these structures are.
acetylation is as frequent as phosphorylation. 9, 15 The lysine residues on the histone proteins which DNA wraps around are especially important sites of acetylation. The defined combination of these histone modifications has been termed the 'histone code'. 16 The histone code can be "read" by proteins, such as bromodomains, but can also be erased and re-written, 17 predominantly by two classifications of cellular enzymes; histone deacetylases (HDACs) and histone acetyl transferases (HATs). If bromodomains are an example of acetylation 'readers', HATs are the 'writers', and HDACs are the 'erasers'. 15 HATs mediate the transfer of acetyl groups onto the lysine residues (histone acetylation), which results in more open and more transcriptionally active chromatin structures, as the interactions between the nucleosomes are altered, and the histone tails are released from the linker DNA. HDAC enzymes remove those acetyl groups (histone deacetylation), repressing transcription due to the formation of a more condensed and transcriptionally silenced chromatin. 3 HDAC inhibitors (HDACis) inhibit the action of HDAC enzymes, resulting in increased acetylation levels in the cell. This may affect the chromatin compaction, linked to the potency, or differentiation potential of stem cells. 9 Despite the misleading name, containing the word 'histone', there are a wide range of non-histone targets of these enzyme. 18 THE STRUCTURE AND ACTIVITY OF HDACS There are 18 human enzymes known to have deacetylation activity, conventionally numbered 1-18 (e.g., 'HDAC8'). Based on molecular phylogenetic analysis of primary structures, their location in the cell and their homology to yeast enzymes RPD3 and HDA1, these 18 HDACs are grouped into four classes, 19 which can be further subdivided into two categories-classical (classes I, II and IV) (see Tables 1 and 2 for a summary) and sirtuins (class III). The activity of the classical HDACs depends on zinc ions (Zn 2+ ), whereas the sirtuins utilise nicotinamide adenine dinucleotide (NAD + ), a phosphate linked dinucleotide coenzyme. As they have entirely different mechanisms of action, sirtuins fall outside the scope of this review; only the classical HDACs are reviewed. 20 
HDACIS AND SPECIFICITY
HDACis are typically small-molecular compounds which can bind to and block the action of HDAC enzymes. Some have been isolated from natural sources, such as Trichostatin A (TSA), or designed and synthesised in a laboratory, such as MS-275. 21 When HDACis bind to, or block, the active site (e.g., the zinc ion) of HDAC enzymes, they act to block the deacetylation action of the zinc ion. To date, research has largely focused on non-specific HDACi compounds (pan-HDACis); broad spectrum HDACis which target many of the HDAC isoforms. 22 It is widely accepted that most first generation HDACis, such as Vorinostat (suberanilohydroxamic acid, SAHA) and Romidepsin 23, 24 are relatively isoform unselective. 25 However, the findings can be conflicting, for example, Bradner and co-workers (2010) found some of these HDACis to be selective for certain HDAC isoforms. Discrepancies can arise due to a lack of knowledge of HDAC structure and problems with screening techniques. 19 The structure of several commercially available HDACis can be seen in Fig. 1 , showing Sodium butyrate, Valproic acid (VPA), Trichostatin A (TSA), Romidepsin, Entinostat (MS-275) and Vorinostat (also known as Zolinza® or suberoylanilide hydroxamic acid, SAHA).
Whilst some pan-HDACis have proven effective drugs, 23, 24 research is beginning to focus on isoform-selective inhibitors. The structural differences between HDAC enzymes mean that HDACis can be designed to be selective for specific enzymes. It has been argued by many that targeting specific HDACs is key to the development of future HDAC therapeutics. 22, 25, 26 Some HDACis, (perhaps most extensively Vorinostat), have been explored in clinical trials as cancer treatments. High levels of deacetylation activity have been linked to tumour pathology and utilising HDACis to reduce deacetylation activity which allows cancer suppressing genes to work. 27 The anti-cancer action of HDACis is also due to many other effects of the compounds on cancer cells, including induction of senescence, activation of apoptosis and mitotic cell death, growth arrest and antiangiogenesis effects. 28 Moving on from their applications in oncology, recent publications have shown the huge potential of using HDACis in other fields, such as tissue engineering. The effects of HDACis can be selective for cancerous cells, even at very low doses, and so the concentrations optimised to affect tumour cells typically do not affect normal cells, and their effect on stem/progenitor/normal somatic cells is often unexplored. 24, 29, 30 THE POTENTIAL OF USING HDACIS IN TISSUE ENGINEERING HDACis affect many cellular properties, such as the cell cycle, proliferation rates, gene expression, differentiation potential, Cellular proliferation, 195, 196 and cell cycle regulation and haematopoiesis 197, 198 DNA damage response, 199 cardiac development 115, 119 Oligodendrocyte, glial cell, synapse and neuronal cell development and function, 146, 148, 154, 155, 158, 200 regulating Schwann cells 156, 201 Osteogenic and skeletal muscle development, 99, 202 cartilage formation 43 Modulating T cell response, 203 Cell cycle regulation, 198 DNA damage response, 199 cardiac development 115, 117 Oligodendrocyte, glial cell, synapse and neuronal cell development and function, 146, 148, 154, 155, 158, 160, 206 regulating Schwann cells 151, 201 Skeletal muscle development, 202 43 Also worth noting from a translational tissue engineering perspective are the reports of HDACis demonstrating pain relief, [44] [45] [46] [47] [48] anti-microbial, 49 immunemodulatory [50] [51] [52] [53] and anti-inflammatory properties. 7, [53] [54] [55] Relative to other tissues, a reasonable volume of research has been undertaken into the link between different HDAC enzymes and bone, cardiac and neural/nervous tissues, and further, tissue engineering. Thus, this review article will focus on these three key areas, looking at the history, current status of in vitro and in vivo research, and finally with a nod to future perspectives.
HDACS AND HDACIS IN BONE TISSUE FORMATION AND REGENERATION
There is still an unmet major clinical need to regenerate bone tissue for fracture repair and the restoration of bone loss due to injury, congenital disorders and degenerative diseases. Researchers currently typically utilise chemicals such as dexamethasone, ascorbic acid and phosphate sources, 56, 57 as well as osteogenic growth factors such as bone morphogenetic proteins to stimulate osteogenic differentiation of stem cells toward bone forming cells. 58 These osteoblast-like cells can produce collagen matrix and modulate matrix mineralisation and maturation. 59 However, the current technologies either have limited efficacy, or adverse side effects, resulting in a search for additional or alternative approaches enhancing bone tissue engineering.
History
Osteoblasts and osteoclasts are the two main cell types responsible for bone formation (osteoblasts), resorption (osteoclasts) and remodelling (both). Research into the effect of HDACis on bone first began in the 1990s, when sodium butyrate (NaB) was found to promote osteoblast bone formation. 60 Since then, historically, a large number of studies involving HDACis have been to investigate their effect on bone densities, due to initial concerns about the side-effects of HDACis utilised in cancer therapies on bone tissue and density. [61] [62] [63] [64] Some research indicated that SAHA inhibited the growth of bonerelated cell populations, such as human bone marrow stem cells, whilst also having the potential to increase osteogenic differentiation in vitro. However, a study found that SAHA did not affect bone mineral density, and could be a promising tool for both oncological and tissue engineering applications. 65 However, in different animal species, HDACis may affect bone density in different ways. 62 HDAC isoforms and their links with bone It has been suggested that several HDAC isoforms are linked to osteoblast activity, in particular, HDAC3 is thought to be closely linked to bone tissue formation. [66] [67] [68] [69] HDAC3 interacts with Runx2, suppressing osteocalcin production and regulating progenitors to differentiate into osteoblasts. 67, 70, 71 During osteoblast differentiation, HDAC3 activity is reduced, resulting in acetylation of histones 3 and 4. This balance of acetylation can be altered in cells by overexpressing or under-expressing Nuclear Factor of Activated T Cells (NFAT) signalling. 72 Further linking HDAC3 to bone formation, H3, as well as H4, acetylation can promote osteocalcin production, which is essential for bone formation. 73 In vivo HDAC3 knockout reduced osteoblast levels and increased fatty deposits in bone marrow, seriously compromising skeletal health in mice. 68 Another study found HDAC3 to be essential for bone maintenance during ageing when knocked down the mouse bone mass was reduced. 69 Similarly, HDAC1 is downregulated during osteoblast differentiation, making it another potentially interesting bone linked HDAC enzyme to be targeted with specific inhibitors to induce osteoblast differentiation. 74 Another class 1 HDAC, HDAC8 is known to suppress osteogenic-related genes expression, and inhibition of this with VPA promoted osteogenic expression of rat bone marrow stromal cells. Thymus, 219 heart, muscle and lung 211 In embryonic endothelial cells of developing heart, blood vessels, mesenchyme and myocardial layers of heart and in lung tissue, 118 role in developing thymocytes, 219, 220 osteoclast activity, 82 inflammatory macrophages 221 HDAC9 Nucleus and cytoplasm 193 Heart, skeletal muscle and brain 211, 222 Redundant role in heart development, 123 controls genes affected by motor innervation in muscles Expressed in the developing brain with neural oligodendrocyte cells, 168 melanin production in the skin, 233 promotes autophagy-mediated cell survival in neuroblastoma cells 234 IV HDAC11 Nucleus and cytoplasm 193 Brain, 168 heart, skeletal muscle, kidney, 235 T cells 236 Influences immune activation versus immune tolerance 236 Jointly HDAC4 and HDAC5 have been found to play a role in osteoblast differentiation. 76, 77 HDAC4 also specifically controls chondrocyte hypertrophy, which is involved in endochondral ossification during bone formation. 78 Moreover, HDAC6 is linked to the differentiation of MSCs into osteogenic lineages. 79 Moving on from osteoblasts, both class I and class II HDAC enzymes are required for osteoclast differentiation, 80 and Romidepsin, which preferentially inhibits HDAC1 and HDAC2, inhibits osteoclastogenesis. 81 HDAC3 and HDAC7 appear to have opposite effects: suppression of HDAC7 accelerates osteoclast differentiation, while suppression of HDAC3 inhibits osteoclast differentiation. 82 Similarly, other researchers have suggested that HDAC5 and HDAC6 activity will reduce osteoclast differentiation. 83 The Wnt signalling pathway is an extensively studied pathway with a key role in the promotion of osteogenic differentiation of MSCs. The Wnt pathway cross-talks with pathways such as the BMP, Notch and Hedgehog pathways, and causes upregulation of osteogenic mediators Runx2, Dl5x and Osterix, as well as suppressing PPARγ. It is likely that increased knowledge of how HDAC enzymes interact with the Wnt pathway will result in improvements in bone tissue engineering protocols. 84 Current status of in vitro research for HDACis in bone tissue engineering Although the specificity of different HDACis is possibly questionable, 19 it is clear that there are obvious differences in effects between different HDACis on bone-related cells. Reports on the effects of HDACis on bone cells can be conflicting. One study showed that high levels of HDAC acetylation were found to block vitamin D stimulation of osteocalcin production, and thus osteoblast differentiation. 85 Lee HW and colleagues (2006) showed that NaB and TSA increased osteogenic characteristics in rat cell lines, as well as the upregulation of osteoblast marker genes by NaB. 74 NaB can also promote osteogenic differentiation of periodontal ligament fibroblasts, and has the added benefit of modulating inflammatory reactions. 55 Similarly, TSA, MS-275 and VPA have been shown to upregulate pre-osteoblast's osteogenic gene expression. 86 However, other reports suggest that TSA may not induce osteoblasts maturation. 60, 66 Another study found that HDAC2-specific MS-275 stimulates bone regeneration both in vitro and in vivo. 87, 88 Thus, the effects of HDACis on cells are still very complex and require further study.
As previously highlighted, several publications demonstrate that HDACis, such as Trichostatin A (TSA) and NaB, inhibit osteoclast differentiation. 60, 89, 90 In 2007, T Yi and J Baek reported that TSA could actually cause the death of osteoclasts, 91 and Kim et al. (2012) suggested that HDAC2-specific inhibitor (MS-275) can reduce bone absorption. 88 These inhibitory effects on osteoclasts could be utilised to prevent bone loss in inflammatory disease. 92 Although, contradictorily, it has also been shown that TSA promoted the expression of RANKL, a ligand integral to osteoclast formation, function and survival. 93 Another HDACi, Largazole was found to increase the in vitro osteogenic potential of C2C12 cells, a murine mesenchymal progenitor cell line, the authors believe this to be due to an increased expression of Runx2 and BMPs. 94 MSCs can also be derived from dental pulp and have shown great potential for tissue engineering particularly for mineralised tissues such as bone. 56 VPA has been shown to improve the generation of mineral matrix in dental pulp MSCs, as well as promoting the expression of some osteogenic bone markers such as osteopontin (OPN) and bone sialoprotein (BSP), albeit with a decrease in osteocalcin (OC) expression. It was also demonstrated that shRNA silencing of HDAC2 lead to increased expression of OPN and BSP, but also the downregulation of OC. 95 TSA has also been shown to promote proliferation and differentiation odontoblasts in DPSCs, 96 and VPA and TSA have been demonstrated to increase mineralisation of murine dental pulp-derived cell line (MDPC-23) cells. 35 A recent review of this area has suggested how bone-related markers and HDACs in hPDLs and DPSCs change during odonto/osteogenic differentiation. 97 It is clear that the choice of HDACi, delivery system and the length of time that cells are exposed to the HDACis may be vital for utilising HDACis in bone tissue engineering. 98 Several in vitro studies demonstrate the importance of controlling the length of time cells that are exposed to the HDACis, leading to researchers often developing pre-treatment strategies to effect differentiation in in vitro protocols. [99] [100] [101] Current status of in vivo research for HDACis in bone tissue engineering In the literature, it is not uncommon for in vivo and in vitro studies to contradict each other. Building on previous work by the group, 101 one of the key first studies utilising HDACis in bone tissue engineering in 2006 reported that the pan-HDACis TSA and NaB increased osteogenic differentiation of MSCs in vitro and ex vivo, however, these results could not be recreated in in vivo conditions.
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In 2010, Hung HM et al. observed an increased osteoblast differentiation when the α-calcium scaffolds with HDACis TSA and NaB were placed in rat bone defect models. 98 Elsewhere in both an in vitro and in vivo study, HDACis NaB and VPA have been used in combination with reduced oxygen environments and adiposederived stem cells to achieve the regeneration of bone tissue. 100 Backing up their in vitro findings, Lee et al. (2011) found that when collagen scaffolds soaked in Largazole solution were implanted in mouse models, there was improved bone formation. 
HDACS AND HDACIS IN HEART TISSUE FORMATION AND REGENERATION
There is a great demand to be able to develop cardiac tissue engineering and regeneration therapies, as heart disease is a major killer worldwide. 102 It has been suggested that HDAC proteins are key in cardiac tissue development and repair, 103 as well as the prevention of degenerative cardiac diseases. 104 For example, HDAC activity has been linked to ischaemic injury, which kills 1 million Americans a year. 105 HDACis have potential as drugs for treatments of cardiac diseases, [106] [107] [108] [109] [110] as well as in improving cardiac tissue engineering, 31, 104, 111 although there is a complicated epigenetic landscape to be understood with each indicated disease associated with the heart. 112 History Cardiac tissue engineering is challenged with selecting a suitable cell type and obtaining and maintaining enough viable cardiomyocytes from stem cell populations. Currently, chemicals such as 5-azacytidine, or other methods such as the coculture of MSCs with mature cardiac muscle cells have been utilised, in an attempt to control stem cell differentiation. 102, 113, 114 However, these methods have yielded inconsistent results. Some studies show that there may be a link between HDAC enzymes and cardiac differentiation, therefore a potential to utilise HDACis for cardiac tissue engineering and regeneration. 31, 104, 111 Also, such processes are very complicated, and research is far from being able to create functional cardiac tissue.
HDAC isoforms and their links with cardiac tissue HDAC1 knockout mice die early in embryogenesis at embryonic day 9.5 due to cardiac defects. HDAC2 deletion leads to survival to the perinatal stage (shortly after birth), but a subsequent death due to a variety of cardiac defects. Cardiac tissue-specific deletion of HDAC1 or HDAC2 alone resulted in no effect on the heart, but deletion of both together resulted in cardiac defects. 115 Some reports suggested that activity of the class IIa HDACs (HDAC4, 5, 7 and 9) suppress cardiac hypertrophy (heart wall thickening) 116 whereas class I enzymes (HDAC1 and 2) promote hypotrophy. 117 Knocking out HDAC7 leads to vascular fatalities in mice. 118 During coculture with cardiomyocytes, expression of HDAC1 decreases in bone marrow MSCs. When HDAC1 was knocked down in these cells, the expression of cardiomyocyte related genes was then significantly increased, further indicating the key role of HDAC1 in the differentiation down this lineage. 119 In both mice and humans HDAC3 is upregulated during endothelial differentiation, and HDAC7 was upregulated during smooth muscle differentiation. 103 HDAC3 is a regulator of cardiac myocyte proliferation during cardiac development in mice 120 and, also in mice, is essential to the maintenance of cardiac function and cell metabolism.
121 HDAC4, and HDAC5 in particular are known to be highly expressed in the heart tissue. 122 Individually knocking out HDAC5 and HDAC9 caused mice to become sensitive to cardiac stress signals, and knocking down both resulted in severe defects, suggesting overlapping functions in cardiac tissue development. 123 To date, the vast majority of reports studying HDAC isoforms and heart tissue have been carried out in mouse models; however, there are obvious differences between the mouse and the human. 124 Different methods of assessing the role of HDAC knockdown may also affect results. 125 Thus, the findings of these studies may not represent the true role of HDACis on human heart disease and development.
Current status of in vitro research for HDACis in cardiac tissue engineering TSA is the most studied HDACi in this field; along with SAHA, it has been found to have a strong effect on cardiogenic induction of rat MSCs when compared with the conventional 5-azacytidine protocol. 111, 126 Interestingly, pre-treatment of rat MSCs with 5-azacytidine enhances the effect of TSA on MSC carcinogenesis, and improvements were also demonstrated when adding TSA treatment to the coculture of MSCs and neonatal cardiomyocytes protocol. 111 These researchers suggest that the combination of HDACis with existing methods could be the future of this research.
TSA has been utilised to stimulate the differentiation of human adipose-derived stem cells into cardiomyocytes. 127 TSA has also been shown to induce other cardiac cell type differentiation (e.g., endothelial and smooth muscle cells) from cardiac side population stem cells. 128 In 2010, Kaichi et al. reported that TSA could reduce inconsistencies and greatly improve the quality of mouse cardiomyocytes differentiated from mouse iPSC lines. 129 Perhaps even more interestingly, a short term treatment of human or mouse embryonic stem cells (ESCs) with TSA can dramatically promote the differentiation of these ESCs into cardiomyocytes, and further increase the cardiac function of the resulting cardiomyocytes. [130] [131] [132] Furthermore, the use of TSA with mouse embryonic carcinoma stem cells promoted cardiac development; however, the upregulation of HDAC4 specifically decreased cardiomyogenesis. 133 Aside from TSA, Chow and co-workers (2013) used VPA to promote the maturation of human ESC-derived ventricular cardiomyocytes. Interestingly, they also suggest that this may be context dependent and that the developmental stage of the cells being treated could influence the outcome. 124 Current status of in vivo research for HDACis in cardiac tissue engineering There has been limited in vivo validation of the potential of HDACis in cardiac repair. Lee et al. (2007) proved that VPA and tributyrin had a positive effect on the remodelling of damage rat ventricles. 12 Further work has shown TSA can improve ventricular function recovery in a defect model, which was found to be c-kit signalling dependent. Conflicting reports: with a low efficacy to HDAC8 in some studies, 238 or as specific to HDAC1, HDAC3 and HDAC8, 239 or a high level of targeting many Class I and Class II HDACs 19 
Romidepsin
Class I FDA anticancer agent used to treat various lymphomas 237 Entinostat (MS-275) HDAC1, HDAC2 and HDAC3 Widely reported as an isoform-specific HDACi 237, 238 Vorinostat (SAHA) HDAC1, HDAC2, HDAC3, HDAC6 and possibly HDAC7
Specificity has conflicting reports-some report as Class I, II and IV, others just HDAC1, HDAC2, HDAC3 and HDAC6. 19 Multiple reports of just targetting HDAC7 also reported 30 
HDACS AND HDACIS IN THE BRAIN, AND NERVOUS TISSUE FORMATION AND REGENERATION
The typical mammalian nervous system of the body is made up of several distinctly different tissue types: the brain and the spinal cord make up the central nervous system (CNS), separate from the peripheral nervous system (PNS), which exists to relay information to and from the CNS. 135 Researchers are struggling to develop effective strategies to heal injuries, or generate tissue from both the CNS and the PNS. Investigations have shed some light onto key HDAC enzymes in these tissues and cell populations, often drawing on the fact HDACis (particularly VPA) have historically actually been used for the treatment of various neurological diseases. 136, 137 History HDACis have been used in the treatment of neurodegenerative diseases since the 1970s, primarily used to prevent neuron damage. 138 Although VPA earned FDA approval in 1987 for its use as an anticonvulsant and mood stabiliser, 21 it was not until 2001 that histone deacetylation inhibition was identified as the mode of action of VPA, resulting in its reclassification as a HDACi. 139, 140 Tissue engineering of these very complicated tissues is a relatively undeveloped area (especially when compared to the previously discussed bone and heart tissues), and differentiation protocols are still being refined and developed. For nervous tissue engineering, current research mainly focuses on the use of nerve guide conduits in combination with different growth factors. 141 Hu et al. (2012) reported that there might be potential for epigenetic control to be exploited in nervous tissue engineering. 142 However, the CNS has a much lower regenerative capacity than the PNS, and current therapies focus mainly on preventing neurodegeneration, rather than actual full regeneration. Regeneration with stem cells and biodegradable and bio-absorbable materials such as polyethene, collagen, gelatin, and chitosan have been explored in the brain and spinal cord, but there is a vast volume of work to be done. 143 HDAC isoforms and their links with neural and nervous tissue HDAC enzymes play a key role in neural cell formation in mouse ESCs. 144 Some HDACs (e.g., HDAC1, HDAC3, HDAC5 and HDAC7) are highly expressed in neural stem cells but are downregulated as neuronal cells differentiate, and therefore are thought to play a role in neuronal differentiation. 145, 146 More specifically, HDAC1 induces the differentiation of retinal progenitor cells and motor neurons in zebrafish development.
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HDAC1 and HDAC2 are linked to neural stem and progenitor cells and synaptic formation, but only HDAC1 is expressed in fully differentiated glia. 146, 148 However, HDAC2 is upregulated in neuronal differentiation, while HDAC1, HDAC3, HDAC5 and HDAC7 are downregulated. [149] [150] [151] [152] [153] In mice, HDAC1 and HDAC2 activity are required for oligodendrocyte differentiation, as well as Schwann cell development. 154, 155 They are also regulators of myelination in the peripheral nervous system. 156 However, other researchers report that, in general, HDAC activity inhibits the differentiation of oligodendrocytes to neurons.
157 HDAC2 activity may be related to the differentiation of neural progenitors, 151, 153 and can inhibit astrocyte differentiation. 154 Knockout of both HDAC1 and HDAC2 in mice neuronal precursor cells leads to cell abnormalities, disorganisation and postnatal mouse fatality. 158 Individually knocking down HDAC1 or HDAC2 also affects neuronal development of mice. 159, 160 HDAC3 is key to neuronal survival, control of apoptosis, and is linked to neural disease, 161 and memory function. 162 HDAC3, together with HDAC1 and HDAC2, has been linked to cortical cell differentiation. 154 HDAC8 is not found to be expressed in normal cells from the central or peripheral nervous system, but is linked to related cancers, notably childhood neuroblastoma, so could be a promising target in this field. 26, 163 Caution should be exercised when exploring HDACis in this field, as it has been demonstrated that targeting class I HDACs with inhibitors in human oligodendrocyte progenitor cells leads to a reduction in progenitor recruitment via proliferation arrest, and inhibition of differentiation into oligodendrocytes. Consequently, Conway and co-workers emphasis that it is also important to realise that there are subtle differences between species in regulation of HDAC activity. 157 Of the class II HDACs, HDAC4 is key, to neuronal activity, and highly expressed in the brain, in neurodegenerative disorders, and HDAC4 activity is thought to provide the neurons protection from cell death by preventing abortive cell cycle progression. 164 HDAC5, HDAC6 and HDAC7 are all linked to neural diseases, such as Huntingdon's disease, protein aggregated diseases and to neural mitochondrial-related diseases respectively. 163 HDAC5 mediated pathways are linked to early-stage neural cell fate. 165 HDAC6 has a complicated role in these systems with both a neuroprotective and neurodegenerative role. 166 HDAC9 is highly expressed in the brain and is proposed to be important in the formation of nerve synapses. 167 Interestingly, the only class IV HDAC, HDAC11, is barely expressed in precursors to neural cells, but largely features in mature neurons, and therefore is thought to be key to postnatal development of neurons. 168 Current status of in vitro research for HDACis in neural and nervous tissue engineering Neural stem cells were first isolated and reported in the early 90s, 169, 170 and subsequently several related other distinct cell populations have since been discovered. 171, 172 Due to the importance of different HDAC isoforms in neuronal and nervous tissue development, the use of specific HDACis could be an especially promising approach for improving the current approaches in tissue engineering. However, so far, only limited studies into the effects of HDACis on relevant neuronal cells have been undertaken.
As Valproic acid (VPA) obtained FDA approval for treating neurological diseases in the 1980s, there has been a relatively large volume of work on the effects of VPA on cells of these systems. 173 VPA can induce neuronal differentiation of adult rat hippocampal neural progenitor cells whilst inhibiting glial cell differentiation; favouring neuronal differentiation. 32 VPA can alter cell function and microglial phenotype of fully developed human glial cells, although it does not result in apoptosis as shown in rodent cells. 174 In a different study, VPA was shown to enhance rat cerebral cortex neural progenitor cell neural differentiation both in vitro and in vivo. 175 Moreover, VPA has been shown to control oligodendrocyte progenitor differentiation. 150 VPA induces proneural factors in rat cells, specifically it has been shown that early stage progenitor cells are more sensitive to the effects of HDAC inhibition, which is thought to be linked to H4 acetylation. 176 Juliandi and co-workers (2012) reported that VPA treatment enhanced the differentiation of mouse-derived ESCs into neuronal lineage layers. 177 However, VPA has also been demonstrated to inhibit proliferation, cell "stemness" and the ability to form neurospheres of mice adult subventricular zone cells, a separate neural cell population. 178 Finally, it has been demonstrated that VPA increases axonal growth of neurons in vitro. 179 Similar to VPA, TSA has also been utilised to induce mouse neural cells (in minimal supplement media) to express some of the properties of fully functioning neurons. 180 In a separate study, Siebzehnrubl et al. (2007) found that the HDACis MS-275, M344 and SAHA induced the neuronal differentiation of mouse forebrain precursor cells. 181 Also, HDACi treatment has been combined with extrinsic transcription factors to promote mouse neural cells to differentiate into dopaminergic neurons. 182 When treated with HDACis, mouse cells showed increased plasticity, reversed lineage commitment and upregulation of 13 genes associated with neural stem cell states, e.g., Sox2. 183 Interestingly, HDAC1 and HDAC2 inhibition can be detrimental to oligodendrocyte differentiation. 157, 183 However, in comparison, HES5 (a notch regulator) was not upregulated in human cells. Thus, once again in this field, it is important to note that not all animal cell models may be directly translatable into human models. 157 Current status of in vivo research for HDACis in nervous tissue engineering Unsurprisingly, given the limited number of in vitro studies, there is only a handful of in vivo studies specifically related to tissue engineering and/or regeneration. An in vivo model of the aforementioned in vitro study demonstrated that VPA regulates differentiation and proliferation of rat cerebral cortex neural progenitor cells in the cerebral cortex of developing rat embryos. 175 VPA has also been proven to reduce cell apoptosis and increase locomotion recovery in a rat spinal cord injury model. 184 VPA has also been shown to increase the differentiation of NSCs into neurons, not glial cells, along with improved limb function, in mouse spinal cord injury models. 185 
A BRIEF DISCUSSION OF THE ROLE OF HDACS AND HDACIS IN SKELETAL MUSCLE
Skeletal muscle tissue formation is also regulated by signalling pathways such as Wnt, BMP and the Class II HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) are highly expressed in skeletal muscle. HDACs play a key role in the epigenetic regulation of embryonic myogenesis and adult muscle regeneration. 186 For example Class II HDACs are known to directly bind myocyte enhancer factor-2 (MEF2) and consequently repress expression of MEF2-dependent genes. 187, 188 HDAC enzymes and their signalling pathways play a key role in regulating myocyte differentiation and remodelling of muscle tissue. 187, 189 HDAC4, in particular, is necessary for maintaining skeletal muscle homoeostasis and function. And it has been identified as a potential target for treatment of skeletal muscle disorders such as cancer cachexia, amyotrophic lateral sclerosis (ALS) or muscular dystrophy. 190 
SUMMARY
In these three key tissue areas, it has been demonstrated HDACis could be very useful tools to improve tissue engineering strategies. Since bone tissue engineering has found early success with studies combining MSCs with HDACis, 11, 100, 101 there is potential to translate this research into clinical settings. Similarly, for cardiac tissue engineering, the many studies involving TSA is a strong beginning for this field, 108 and when isoform-specific strategies begin, HDAC4 in particular has proven a potentially interesting target for cardiac tissue engineering. 122 Regarding neural tissue engineering, most of the studies have explored the use of VPA, which is considered a pan-HDACi. Therefore, it is believed that selective isoform targeting may lead to improvements in this field. 163, 191 Presently, researchers aim to combine suitable cells (e.g., MSCs) with scaffolds, chemical cues (e.g., growth factors) and environmental stimuli (e.g., mechanical stimulation) to general functional tissue, such as new nerves, bone and other muscular-skeletal tissues in dentistry and/or orthopaedics. This can be carried out in vitro before being implanted/transplanted in vivo, where the naturally occurring cells can populate the scaffold and chemical cues aid the growth of the targeted tissues. Therefore, HDACis could be utilised as the chemical cues to improve the efficacy of current tissue engineering techniques.
FUTURE PERSPECTIVES
There has been some early success stories utilising HDACis in tissue engineering, but looking to the future, the rise of isoformspecific HDACis may lead this research to new heights. There is still plenty to be said for the classical HDACis; however, the connection between tissues and specific HDAC isoforms should lead to more examples of targeted tissue engineering scenarios.
The current limitations of the technologies must be considered:
• a lack of understanding of the pathways HDAC enzymes themselves are involved in, and the effects of these enzymes on cellular properties and behaviour;
• a fundamental lack of knowledge of the function of individual HDAC enzymes, in different cell/tissue types;
• the mechanism of action of many HDACis, i.e., how panHDACi's function, what HDAC isoforms each actually inhibits, and therefore their true mechanisms of action;
• full optimisation of the desired concentration and treatment period of each HDACi on individual cells, to give the best outcome; and
• the need for extensive in vivo testing in clinically relevant animal models, with particular attention to the side effects, before the translation of any HDACis for clinical therapies in this area.
CONCLUSION
In conclusion, the field of HDACis in tissue engineering is still in its infancy compared with cancer research where at least 4 HDACis have achieved clinical approval, with many others in late-stage clinical trials. 192 As demonstrated herein, easily synthesised smallmolecular compounds in low concentrations could massively improve the efficacy of stem cell therapies and tissue engineering, potentially without the risks associated with genome altering therapies. As discussed at length in this review, there is a potential paradigm shift in this field with the rise of isoform-specific HDACis. As more regulatory barriers are cut, due to increased clinical approval of HDACis, the potential to translate these compounds in other filed such as in tissue engineering has been increased.
